Merck Millipore's Strat-M Membrane as Effective as Skin for Permeation Studies
Merck Millipore has announced publication of a study showing that its Strat-M synthetic membrane predicts skin permeation of chemical compounds during in vitro transdermal diffusion studies as effectively as human or animal skin. The study was conducted by researchers at Josai University in Japan and published in the 25 January 2015 issue of European Journal of Pharmaceutical Sciences.
Strat-M membrane is a synthetic, non-animal-based model that is predictive of diffusion in human skin for a wide range of compounds and formulations, including active pharmaceutical ingredients, cosmetic actives, personal care products, pesticides and other chemicals. The membrane provides highly consistent, reproducible diffusion data without the lot-to-lot variability that often occurs with biological models.
The new study evaluated the ability of Strat-M membrane to serve as an alternative to human and animal skin for estimating the skin permeability of different chemical compounds. Thirteen compounds were tested on excised human skin, hairless rat skin and Strat-M membrane. Permeability coefficients obtained with Strat-M membrane could be used to predict those obtained from the human and rat skins.
"In vitro skin permeation studies are essential to development of new transdermal delivery systems," said Kenji Sugibayashi, author of the study, Professor of Pharmaceutical Sciences at Josai University, and renowned expert on skin permeation. "Biological models are often used to conduct this research, but there are various drawbacks, including high variability, low availability, safety considerations and storage limitations." Study co-author Dr Hiroaki Todo added: "Our study suggests that Strat-M membrane can serve as an alternative to human and animal skin in permeation studies, offering researchers a valuable tool for screening candidate compounds."
"Drs Sugibayashi's and Todo's peer-reviewed research confirms that Strat-M membrane can be used for transdermal diffusion testing," said Patrick Schneider, Head of Bioscience at Merck Millipore. "Published results supporting the membrane's application will increase awareness and accelerate adoption by the research community, facilitating in vitro testing of transdermal formulations."
Introduced in 2012, Strat-M membrane is constructed of multiple layers, creating morphology similar to human skin. Strat-M membrane is individually packaged as precut discs that are easy to store and do not need to be hydrated prior to use.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance